About this Research Topic
Acute stress is useful for the fight and flight response in the short term, but long-term stress exposure contributes to the pathophysiology of psychiatric disorders, particularly anxiety, and depression. Additionally, stress is reported to increase the use and abuse of addictive drugs and plays a major role in negative affective states associated with drug withdrawal. Furthermore, stress is one of the leading causes of drug craving and relapse. However, the underlying mechanisms of stress-mediated psychiatric disorders are not fully characterized. Thus, further research is needed in this area.
Several studies have implicated some neuropeptides, e.g., corticotropin release hormone (CRH, also known as CRF), dynorphin, orphanin FQ/nociceptin, pituitary adenylyl cyclase activating polypeptide (PACAP), orexin, enkephalin to name a few, in stress-mediated psychiatric disorders. Therefore, the goal of this Research Topic is to advance our understanding of the role of neuropeptides in stress-related psychiatric disorders, with a focus on anxiety, depression, and addictive behaviors.
Stress is one of the leading causes of psychiatric disorders, anxiety, depression, drug abuse as well as craving and relapse. However, there is limited pharmacotherapy to treat these conditions. This may be because the underlying mechanisms of stress-mediated psychiatric illnesses are not fully elucidated. Many neuropeptides have been implicated in the stress response as well as in the pathophysiology of psychiatric disorders. However, the role of these chemicals in stress-mediated drug use, craving and relapse as well as in negative affective states associated with drug withdrawal is not fully characterized. Thus, this Research Topic aims to define the role of neuropeptides in neuropsychiatric disorders as well as drug use, craving, and relapse as well as in anxiety and depression associated with drug withdrawal.
We welcome to submit manuscripts in the form of Original Research or review papers encompassing one of the following themes:
- Reporting on the changes in the level of peptides or their receptors following repeated stress.
- Altering stress-mediated drug use, craving and relapse targeting neuropeptides and their receptor agonists or antagonists.
- Studying changes in the level of neuropeptides or their receptors following drug withdrawal.
- Treating negative affective signs of withdrawal by neuropeptides and their receptor agonists or antagonists.
- Determining the impact of temporal changes in the level of neuropeptides and their receptors on stress-mediated anxiety, depression, drug use, craving and relapse, as well as negative affective signs of withdrawal.
- Characterizing of novel neuropeptides and determining their role in stress-mediated anxiety, depression, drug use, craving and relapse, as well as negative affective signs of withdrawal.
Several studies have implicated some neuropeptides, e.g., corticotropin release hormone (CRH, also known as CRF), dynorphin, orphanin FQ/nociceptin, pituitary adenylyl cyclase activating polypeptide (PACAP), orexin, enkephalin to name a few, in stress-mediated psychiatric disorders. Therefore, the goal of this Research Topic is to advance our understanding of the role of neuropeptides in stress-related psychiatric disorders, with a focus on anxiety, depression, and addictive behaviors.
Stress is one of the leading causes of psychiatric disorders, anxiety, depression, drug abuse as well as craving and relapse. However, there is limited pharmacotherapy to treat these conditions. This may be because the underlying mechanisms of stress-mediated psychiatric illnesses are not fully elucidated. Many neuropeptides have been implicated in the stress response as well as in the pathophysiology of psychiatric disorders. However, the role of these chemicals in stress-mediated drug use, craving and relapse as well as in negative affective states associated with drug withdrawal is not fully characterized. Thus, this Research Topic aims to define the role of neuropeptides in neuropsychiatric disorders as well as drug use, craving, and relapse as well as in anxiety and depression associated with drug withdrawal.
We welcome to submit manuscripts in the form of Original Research or review papers encompassing one of the following themes:
- Reporting on the changes in the level of peptides or their receptors following repeated stress.
- Altering stress-mediated drug use, craving and relapse targeting neuropeptides and their receptor agonists or antagonists.
- Studying changes in the level of neuropeptides or their receptors following drug withdrawal.
- Treating negative affective signs of withdrawal by neuropeptides and their receptor agonists or antagonists.
- Determining the impact of temporal changes in the level of neuropeptides and their receptors on stress-mediated anxiety, depression, drug use, craving and relapse, as well as negative affective signs of withdrawal.
- Characterizing of novel neuropeptides and determining their role in stress-mediated anxiety, depression, drug use, craving and relapse, as well as negative affective signs of withdrawal.
Keywords: neuropeptides, stress-mediated, psychiatric disorders
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
